Lia Tsimberidou, MD [7505]


What is the available evidence supporting the rationale for comprehensive molecular profiling across a broad continuum of solid tumor subtypes?

What is the available evidence supporting the rationale for comprehensive molecular profiling across a broad continuum of solid tumor subtypes?

Can you share specific patient examples where molecular profiling has affected a clinical treatment decision and produced a favorable outcome?

Can you share specific patient examples where molecular profiling has affected a clinical treatment decision and produced a favorable outcome?

How do technology platforms --from hot spot panels to FoundationOne--for characterizing molecular drivers differ; and why do NGS-based hybrid capture platforms offer the most reproducible and actionable results?

How do the different technology platforms —from hot spot panels to FoundationOne—for characterizing molecular drivers differ; and why do NGS-based hybrid capture platforms offer the most reproducible and actionable results?

In addition to the molecular alterations identified by the NGS, what additional information is provided by these reports that is critical to drug selection?

In addition to the molecular alterations identified by the NGS, what additional information is provided by these reports that is critical to drug selection?

How do we curate the results of NGS-based genomic profiles? How do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability?

How do we curate the results of NGS-based genomic profiles? In particular, how do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability? Is there a ...

At what stage of a cancer's presentation is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations?

At what stage of a cancer’s presentation or evolution is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers?

Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers that may have treatment implications?

How do you approach drug selection decisions when you encounter multiple actionable targets?

How do you approach drug selection decisions when you encounter multiple actionable targets?